IDH1 and acute myeloid leukemia: Instead, to counteract the aberrant DNA hypermethylation caused by 2-HG production in IDH1/2 mutant cancers, promising IDH1/2 mutant inhibitors are available, and Ivosidenib has been recently approved from FDA for acute myeloid leukemia [153].